Cellmid Limited  

(Public, ASX:CDY)   Watch this stock  
Find more results for William N. Lucy
0.0000 (0.00%)
Oct 9 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.03 - 0.03
52 week 0.02 - 0.04
Open 0.03
Vol / Avg. 190,000.00/1.45M
Mkt cap 30.64M
P/E     -
Div/yield     -
EPS 0.00
Shares 893.17M
Beta     -
Inst. own     -
Nov 12, 2015
Cellmid Ltd Annual Shareholders Meeting Add to calendar
Oct 9, 2015
Cellmid Ltd Annual Shareholders Meeting (Estimated)

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin -182.00% -169.46%
Operating margin -178.45% -218.14%
EBITD margin - -211.47%
Return on average assets -72.91% -52.97%
Return on average equity -96.19% -70.72%
CDP Score - -


City Freehold Se 1802 L 18, 15 Castlereagh St
+61-2-92216830 (Phone)
+61-2-92218535 (Fax)

Website links


Cellmid Limited is an Australia-based biotechnology company focused on oncology. The Company operates in two segments: research and development of diagnostics and therapeutics, and research, development and marketing of hair growth products. The Company is engaged in development and commercialization of diagnostic and therapeutic products for the management of diseases, such as cancer and various chronic inflammatory conditions by targeting midkine (MidkineBusiness), and the development and sale of over-the-counter (OTC) treatments to alleviate excessive and abnormal hair loss and re-establish the natural hair growth cycle (consumer health business). The Company's products include Midkine ELISA kit, Advangen International hair loss products and Evolis products.

Officers and directors

Maria Halasz Chief Executive Officer, Managing Director, Executive Director
Nicholas Falzon Financial Controller
Lucy N. Rowe Company Secretary
David William King Independent Non-Executive Chairman of the Board
Bruce Gordon Non-Executive Director
Edward Fintan Walton Non-Executive Director